Literature DB >> 22902910

Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.

Bo-Eric Persson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22902910      PMCID： PMC3734989          DOI： 10.1038/aja.2012.53

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  7 in total

1.  Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Authors:  Matthew R Smith; Laurence Klotz; Egbert van der Meulen; Enrico Colli; László B Tankó
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

2.  An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

Authors:  Laurent Boccon-Gibod; Egbert van der Meulen; Bo-Eric Persson
Journal:  Ther Adv Urol       Date:  2011-06

Review 3.  Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Authors:  Roisin M Connolly; Michael A Carducci; Emmanuel S Antonarakis
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

4.  A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Authors:  E David Crawford; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Fritz Schröder; Neal Shore; Judd W Moul; Jens-Kristian Jensen; Tine Kold Olesen; Bo-Eric Persson
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

5.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

Authors:  Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Fritz Schröder; Neal Shore; E David Crawford; Judd Moul; Jens-Kristian Jensen; Tine Kold Olesen; Bo-Eric Persson
Journal:  Eur Urol       Date:  2009-11-20       Impact factor: 20.096

6.  The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Authors:  Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder
Journal:  BJU Int       Date:  2008-12       Impact factor: 5.588

7.  Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Authors:  Fritz H Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D Shore; E David Crawford; Judd Moul; Tine Kold Olesen; Bo-Eric Persson
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.